MedTrace Logo

A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel

NCT00427050 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-09-14

No results posted yet for this study

Summary

The purpose of this study is to determine the optimal tolerated regime of PEP005 for the treatment of actinic keratoses of the face or face and scalp.

Conditions

  • Actinic Keratoses

Interventions

DRUG

PEP005

Sponsors & Collaborators

  • Peplin

    lead INDUSTRY

Principal Investigators

  • Janelle Katsamas · Peplin Operations Pty Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427050 on ClinicalTrials.gov